Key Points
- Director Mark Christianson sold 10,000 shares of NeuroOne Medical Technologies at an average price of $3.18, totaling $31,800. After the sale, he still held 20,692 shares, a 32.58% reduction in his ownership.
- NeuroOne reported weaker-than-expected quarterly results, posting a loss of $0.25 per share versus the $0.23 consensus estimate and revenue of $1.86 million, below expectations of $2.58 million.
- Analyst sentiment is mixed, with a consensus rating of “Hold” and an average target price of $11.67, even as the stock traded near $3.00 and remained close to its 12-month low.
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC - Get Free Report) Director Mark Christianson sold 10,000 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total value of $31,800.00. Following the completion of the sale, the director owned 20,692 shares of the company's stock, valued at approximately $65,800.56. This represents a 32.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
NeuroOne Medical Technologies Price Performance
Shares of NMTC opened at $3.00 on Friday. The stock's 50-day moving average is $3.84 and its two-hundred day moving average is $4.39. The stock has a market cap of $26.10 million, a PE ratio of -3.53 and a beta of 0.54. NeuroOne Medical Technologies Corporation has a 12 month low of $2.89 and a 12 month high of $6.96.
NeuroOne Medical Technologies (NASDAQ:NMTC - Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%.The company had revenue of $1.86 million during the quarter, compared to analysts' expectations of $2.58 million. On average, research analysts anticipate that NeuroOne Medical Technologies Corporation will post -0.36 earnings per share for the current year.
Institutional Trading of NeuroOne Medical Technologies
Large investors have recently modified their holdings of the business. Legato Capital Management LLC acquired a new position in shares of NeuroOne Medical Technologies in the fourth quarter worth about $34,000. Squarepoint Ops LLC purchased a new position in NeuroOne Medical Technologies in the fourth quarter valued at about $36,000. Susquehanna International Group LLP acquired a new stake in NeuroOne Medical Technologies during the 3rd quarter valued at approximately $47,000. XTX Topco Ltd acquired a new stake in NeuroOne Medical Technologies during the 2nd quarter valued at approximately $51,000. Finally, Goldman Sachs Group Inc. purchased a new stake in NeuroOne Medical Technologies during the 1st quarter worth approximately $84,000. 16.07% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the company. Zacks Research cut NeuroOne Medical Technologies from a "strong-buy" rating to a "hold" rating in a report on Friday, March 13th. LADENBURG THALM/SH SH lifted their price objective on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, May 13th. Finally, Weiss Ratings cut shares of NeuroOne Medical Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday, May 11th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $11.67.
Read Our Latest Analysis on NMTC
About NeuroOne Medical Technologies
(
Get Free Report)
NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company's core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.
The company's flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
